Rani Therapeutics Holdings (RANI) Debt to Equity (2020 - 2025)
Rani Therapeutics Holdings' Debt to Equity history spans 6 years, with the latest figure at -$1.72 for Q3 2025.
- On a quarterly basis, Debt to Equity fell 135.14% to -$1.72 in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.72, a 135.14% decrease, with the full-year FY2024 number at $7.05, up 510.19% from a year prior.
- Debt to Equity came in at -$1.72 for Q3 2025, up from -$1.88 in the prior quarter.
- The five-year high for Debt to Equity was $7.05 in Q4 2024, with the low at -$3.91 in Q1 2025.
- Historically, Debt to Equity has averaged $0.9 across 5 years, with a median of $0.39 in 2022.
- Biggest five-year swings in Debt to Equity: soared 199690.27% in 2023 and later crashed 293.11% in 2025.
- Year by year, Debt to Equity stood at $0.0 in 2021, then soared by 37902.63% to $0.39 in 2022, then skyrocketed by 193.18% to $1.15 in 2023, then surged by 510.19% to $7.05 in 2024, then crashed by 124.44% to -$1.72 in 2025.
- Business Quant data shows Debt to Equity for RANI at -$1.72 in Q3 2025, -$1.88 in Q2 2025, and -$3.91 in Q1 2025.